Maharashtra FDA withdrew its cancellation of Cipla Pharma’s drug sale license after court intervention. The Bombay High Court criticized the regulator for acting high-handedly and violating natural justice principles. The court allowed the FDA to issue a fresh show cause notice and conduct a proper hearing. Cipla’s license cancellation had prevented critical medicines from reaching patients. The FDA’s order was passed on a public holiday without a proper hearing.